Lars Thorsson

1.6k total citations
25 papers, 970 citations indexed

About

Lars Thorsson is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Lars Thorsson has authored 25 papers receiving a total of 970 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Physiology, 16 papers in Pulmonary and Respiratory Medicine and 4 papers in Oncology. Recurrent topics in Lars Thorsson's work include Asthma and respiratory diseases (17 papers), Inhalation and Respiratory Drug Delivery (16 papers) and Respiratory and Cough-Related Research (8 papers). Lars Thorsson is often cited by papers focused on Asthma and respiratory diseases (17 papers), Inhalation and Respiratory Drug Delivery (16 papers) and Respiratory and Cough-Related Research (8 papers). Lars Thorsson collaborates with scholars based in Sweden, Denmark and United Kingdom. Lars Thorsson's co-authors include Lars Borgström, Staffan Edsbäcker, Bo Olsson, Anders Källén, Claes‐Göran Löfdahl, Jennifer R. Paulson, Hans Bisgaard, Stanton Newman, CJ Kenyon and David E. Geller and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Respiratory and Critical Care Medicine and Biochemical Journal.

In The Last Decade

Lars Thorsson

25 papers receiving 898 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lars Thorsson Sweden 15 771 573 76 63 61 25 970
Anton Drollmann Switzerland 14 828 1.1× 693 1.2× 34 0.4× 26 0.4× 27 0.4× 32 981
Larry E. Bowen United States 13 355 0.5× 120 0.2× 85 1.1× 7 0.1× 23 0.4× 27 597
Marek Kasielski Poland 15 380 0.5× 288 0.5× 112 1.5× 7 0.1× 19 0.3× 28 744
Gianluigi Poli Italy 14 520 0.7× 380 0.7× 14 0.2× 32 0.5× 29 0.5× 40 633
Rick Fuller United States 5 268 0.3× 446 0.8× 46 0.6× 21 0.3× 21 0.3× 8 654
R.E.C. Altounyan United Kingdom 11 540 0.7× 667 1.2× 68 0.9× 3 0.0× 48 0.8× 20 1.0k
R. Nave Germany 14 443 0.6× 449 0.8× 30 0.4× 37 0.6× 65 1.1× 41 722
S. Reader United Kingdom 8 220 0.3× 160 0.3× 16 0.2× 21 0.3× 21 0.3× 13 442
B Müllinger Germany 11 249 0.3× 95 0.2× 38 0.5× 9 0.1× 10 0.2× 15 344
Zofia Kurmanowska Poland 14 318 0.4× 364 0.6× 103 1.4× 2 0.0× 8 0.1× 30 645

Countries citing papers authored by Lars Thorsson

Since Specialization
Citations

This map shows the geographic impact of Lars Thorsson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Thorsson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Thorsson more than expected).

Fields of papers citing papers by Lars Thorsson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Thorsson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Thorsson. The network helps show where Lars Thorsson may publish in the future.

Co-authorship network of co-authors of Lars Thorsson

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Thorsson. A scholar is included among the top collaborators of Lars Thorsson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Thorsson. Lars Thorsson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Awada, Ahmad, Sebastian Ochsenreither, Rikke Løvendahl Eefsen, et al.. (2021). 538P Nadunolimab (CAN04), a first-in-class monoclonal antibody against IL1RAP, in combination with chemotherapy in subjects with pancreatic cancer (PDAC) and non-small cell lung cancer (NSCLC). Annals of Oncology. 32. S602–S603. 1 indexed citations
2.
Robbrecht, Debbie, Christiane Jungels, Morten Mau‐Sørensen, et al.. (2021). First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours. British Journal of Cancer. 126(7). 1010–1017. 12 indexed citations
3.
Boorsma, Martin, et al.. (2008). Evidence of the in vivo esterification of budesonide in human airways. British Journal of Clinical Pharmacology. 66(1). 27–35. 35 indexed citations
4.
Emanuelsson, Cecilia Ahlström, Morgan Andersson, C. G. A. Persson, Lars Thorsson, & Lennart Greiff. (2007). Effects of topical formoterol alone and in combination with budesonide in a pollen season model of allergic rhinitis. Respiratory Medicine. 101(6). 1106–1112. 14 indexed citations
5.
Bengtsson, Thomas, et al.. (2007). Exposure of infants to budesonide through breast milk of asthmatic mothers. Journal of Allergy and Clinical Immunology. 120(4). 798–802. 20 indexed citations
6.
Borgström, Lars, Bo Olsson, & Lars Thorsson. (2006). Degree of Throat Deposition Can Explain the Variability in Lung Deposition of Inhaled Drugs. Journal of Aerosol Medicine. 19(4). 473–483. 138 indexed citations
7.
Thorsson, Lars & David E. Geller. (2005). Factors guiding the choice of delivery device for inhaled corticosteroids in the long-term management of stable asthma and COPD: Focus on budesonide. Respiratory Medicine. 99(7). 836–849. 26 indexed citations
8.
Borgström, Lars, Lars Asking, & Lars Thorsson. (2005). Idealhalers or realhalers? A comparison of Diskus and Turbuhaler. International Journal of Clinical Practice. 59(12). 1488–1495. 34 indexed citations
9.
Thorsson, Lars, et al.. (2003). Systemic availability and lung deposition of budesonide via three different nebulizers in adults. Annals of Allergy Asthma & Immunology. 90(2). 226–232. 27 indexed citations
10.
Thorsson, Lars, Staffan Edsbäcker, Anders Källén, & Claes‐Göran Löfdahl. (2001). Pharmacokinetics and systemic activity of fluticasone via Diskus® and pMDI, and of budesonide via Turbuhaler®. British Journal of Clinical Pharmacology. 52(5). 529–538. 133 indexed citations
11.
Thorsson, Lars, et al.. (2000). Lung Deposition of Inhaled Drugs Increases with Age. American Journal of Respiratory and Critical Care Medicine. 162(5). 1819–1822. 60 indexed citations
12.
Thorsson, Lars, et al.. (2000). A randomized controlled assessment of the systemic activity of budesonide when given once or twice daily via Turbuhaler. European Journal of Clinical Pharmacology. 56(3). 207–210. 7 indexed citations
13.
Kenyon, CJ, Lars Thorsson, Lars Borgström, & Stanton Newman. (1998). The effects of static charge in spacer devices on glucocorticosteroid aerosol deposition in asthmatic patients. European Respiratory Journal. 11(3). 606–610. 58 indexed citations
14.
Thorsson, Lars & Staffan Edsbäcker. (1998). Lung deposition of budesonide from a pressurized metered-dose inhaler attached to a spacer. European Respiratory Journal. 12(6). 1340–1345. 55 indexed citations
15.
Kaiser, Harold B., et al.. (1998). Effects of budesonide by means of the Turbuhaler on the hypothalmic-pituitary-adrenal axis in asthmatic subjects: A dose-response study☆☆☆★★★. Journal of Allergy and Clinical Immunology. 101(3). 312–319. 47 indexed citations
16.
Thorsson, Lars, et al.. (1998). Lung deposition of budesonide in asthmatics: a comparison of different formulations. International Journal of Pharmaceutics. 168(1). 119–127. 46 indexed citations
17.
Thorsson, Lars, et al.. (1997). Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. British Journal of Clinical Pharmacology. 43(2). 155–161. 123 indexed citations
18.
Thorsson, Lars. (1995). Influence of Inhaler Systems on Systemic Availability, With Focus on Inhaled Corticosteroids. Journal of Aerosol Medicine. 8(s3). S–29. 11 indexed citations
19.
Thorsson, Lars, et al.. (1993). Nasal distribution of budesonide inhaled via a powder inhaler.. PubMed. 31(1). 7–10. 43 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anton Drollmann Breakdown of academic impact, for papers by Larry E. Bowen Breakdown of academic impact, for papers by Marek Kasielski Breakdown of academic impact, for papers by Gianluigi Poli Breakdown of academic impact, for papers by Rick Fuller Breakdown of academic impact, for papers by R.E.C. Altounyan Breakdown of academic impact, for papers by R. Nave Breakdown of academic impact, for papers by S. Reader Breakdown of academic impact, for papers by B Müllinger Breakdown of academic impact, for papers by Zofia Kurmanowska
Rankless by CCL
2026